微創機器人-B(02252.HK):Mona Lisa前列腺穿刺機器人臨牀試驗啟動並完成首例手術
格隆匯11月24日丨微創機器人-B(02252.HK)宣佈,公司和新加坡Biobot Surgical Pte. Ltd.聯合在華成立的合資公司上海介航機器人有限公司("微創介航機器人")引進的Mona Lisa前列腺穿刺機器人定位系統("Mona Lisa"),已在南京大學醫學院附屬鼓樓醫院("南京鼓樓醫院")成功舉辦了臨牀試驗啟動儀式並完成首例手術,這也是中國國內首例機器人輔助前列腺穿刺活檢臨牀試驗手術。
Mona Lisa是公司在經皮穿刺這一賽道佈局的一款創新機器人產品。前列腺穿刺活檢是前列腺癌診斷的"金標準",目前臨牀實踐中仍普遍採用人工穿刺方式,檢驗效果和併發症發生率與醫生的技術密切相關。此外,人工穿刺的前列腺癌檢出率較低,為減少漏診率,醫生通常必須通過增加穿刺點的方式提高檢出率,且在穿刺期間有刺穿患者尿道或直腸的風險,給患者帶來巨大痛苦。而Mona Lisa可使醫生能夠更加精確、輕鬆地進行活檢取樣:術前,醫生可以通過智慧的軟體進行手術規劃和交互調整;術中,強大的彈性MRI-超聲融合演算法可即時引導醫生,使得目標靶點無論位於前列腺尖部、基底部或外周帶,都能容易且準確地被取樣。創新的經會陰兩點式入針法可以最大限度地減少恥骨弓的干擾、減少患者創口,並實現完全的前列腺覆蓋;術後,Mona Lisa可生成包含3D圖像和臨牀資料的完整報吿。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.